The Human Proteome - A Scientific Opportunity for Transforming Diagnostics, Therapeutics, and Healthcare

Event Details

Purpose

There have been several discussions about the Human Proteome Project and the way that it could extend and build on the success of the Human Genome Project. The fact that proteins are the major components of biological networks and molecular machines, and that proteins are the target for the large majority of drugs available today, strongly indicates that a deeper knowledge of the human proteome and the development of the technologies needed for analyzing large subsets of proteins in a clinical setting could transform the way that we do diagnostics and could substantially enhance the overall health care enterprise.

Several efforts to enhance proteomics technologies have been made in recent years, including the NIH Common Fund-supported Technology Centers for Networks and Pathways program and Protein Capture programs, the Human Protein Atlas Project, the Human Multiple Reaction Monitoring (MRM) Atlas, and the HUPO Human Proteome Project. The best course of action, however, for capitalizing on recent technology developments is not clear. There are indeed many possible opportunities to synergize with these efforts.

Meeting Objectives

Briefly, the main goal of this NIH Workshop is to articulate ways in which members of the biomedical research community can capitalize on recent technology advances and synergize with ongoing efforts to advance the field of human proteomics. If ongoing needs for dedicated funds are identified, a white paper will be developed to articulate these needs. This will be shared with the Institutes and Centers of the NIH for their consideration. The principal purpose of this Workshop is to provide a forum for the community to consider best use of recent technological advances to move the field forward.

Organizers

Salvatore Sechi, Maureen Beanan (NIAID), Laurie Nadler (NIMH), Pothur Srinivas (NHLBI)

Workshop Chairs

Daniel Chan, Johns Hopkins University School of Medicine
Mark Gerstein, Yale University
Matthias Mann, Max-Planck Institute of Biochemistry
Gil Omenn, University of Michigan
Marc Vidal, Harvard University

Agenda

September 26, 2011

8:00 - 8:15 a.m.

Welcome and Workshop Introduction
Mary Perry, Program Director, NIH, OD
Salvatore Sechi, Program Director, NIDDK, NIH

Proteomics in Systems Biology

Subsession 1: Protein Networks

Chair: Marc Vidal, Dana-Farber Cancer Institute

8:15 - 8:35 a.m.

Marc Vidal, Dana-Farber Cancer Institute

8:35 - 8:55 a.m.

Suzanne Gaudet, Dana-Farber Cancer Institute

8:55 - 9:15 a.m.

Kara Dolinski, Lewis-Sigler Institute for Integrative Genomics

Subsession 2: Integrating Proteomics with Other Omics

Chair: Mark Gerstein, Yale University

9:15 - 9:35 a.m.

Mark Gerstein, Yale University

9:35 - 9:55 a.m.

Rolf Apweiler, EMBL Outstation European Bioinformatics Institute (EBI)

9:55 - 10:15 a.m.

Joel Bader, The Johns Hopkins University

10:15 - 10:35 a.m.

Robert Gerszten, Massachusetts General Hospital

10:35 - 10:55 a.m.

Zhiping Weng, University of Massachusetts Medical School

10:55 - 11:15 a.m.

Break

Subsession 3: Quantitative Proteomics by Exploratory and Targeted Methodologies

Chair: Mathias Mann, Max Planck Institute of Biochemistry

11:15 - 11:35 a.m.

Mathias Mann, Max Planck Institute of Biochemistry

11:35 - 11:55 a.m.

Forest White, The David H. Koch Institute for Integrative Cancer Research

11:55a.m. - 12:15 p.m.

Josh Coon, University of Wisconsin-Madison

12:15 - 12:35 p.m.

Rob Moritz, Institute for Systems Biology

12:35 - 1:40 p.m.

Lunch

1:40 - 2:40 p.m.

Panel Discussion
John Quackenbush, Dana-Farber Cancer Institute; Akilesh Pandey, The Johns Hopkins University; Peipei Ping, University of California, Los Angeles; Steve Bryant, National Center for Biotechnology Information, NIH, Stephen Barnes, University of Alabama at Birmingham

Translating Proteomics

Subsession 1: Proteomic Technologies in a Clinical Setting

Chair: Daniel Chan, The Johns Hopkins University School of Medicine

2:40 - 3:00 p.m.

Daniel Chan, The Johns Hopkins University School of Medicine

3:00 - 3:20 p.m.

Barry Dowell, Abbott Laboratories

3:20 - 3:40 p.m.

Darryl Palmer-Toy, Southern California Permanente Medical Group

3:40 - 4:00 p.m.

Maria Chan, U.S. Food and Drug Administration

4:00 - 4:20 p.m.

Break

Subsession 2: Study Design and Statistical Challenges in Clinical Proteomics

Chair: Gil Omenn, University of Michigan

4:20 - 4:40 p.m.

Gil Omenn, University of Michigan

4:40 - 5:00 p.m.

Steven Skates, Harvard University Medical School

5:00 - 5:20 p.m.

Lisa McShane, National Cancer Institute

5:20 - 6:10 p.m.

Brainstorming on Ideas Discussed

September 27, 2011

8:00 - 9:00 a.m.

General Discussion

Additional feedback from the participants to the chairs

9:00 - 11:30 a.m.

Chairs and Organizers Meeting

Chairs Meet to Write Report and Finalize Ideas